###begin article-title 0
Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions
###end article-title 0
###begin p 1
Conceived and designed the experiments: BV SdW CVL YEC. Performed the experiments: BV SdW AR. Analyzed the data: BV SdW AR DO CVL YEC. Wrote the paper: BV SdW DO CVL YEC.
###end p 1
###begin p 2
###xml 505 511 505 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 719 725 719 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 850 857 850 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 977 983 977 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1778 1786 1774 1782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Histone deacetylase inhibitors (HDACi) have demonstrated promising therapeutic potential in clinical trials for hematological malignancies. HDACi, such as SAHA/Vorinostat, Trichostatin A, and MS-275 were found to induce apoptosis of leukemic blasts through activation of the death receptor pathway and transcriptional induction of the Tumor Necrosis Factor (TNF)-related pro-apoptotic family members, TRAIL and FasL. The impact of HDACi on TNF-related costimulatory molecules such as 4-1BB ligand (4-1BBL/TNFSF9) is however not known. Following exposure to SAHA/Vorinostat, Trichostatin A, and MS-275, transcript levels were determined by real time PCR in Jurkat, Raji and U937 cells. Treatment with HDACi up-regulated TNFSF9 gene expression in the three leukemia cell lines, yet to different extend and with distinct kinetics, which did not require de novo protein synthesis and was not associated with DNAse I hypersensitive chromatin remodeling. Transcriptional activity of TNFSF9 promoter-luciferase constructs was induced up to 12 fold by HDACi, and implication of Sp1/Sp3 transcription factors binding to functional GC-box elements was evidenced by reporter gene assays, site-directed mutagenesis, and electrophoretic mobility shift assays. Functionality of modulated target genes was assessed in allogeneic mixed leukocyte reaction experiments. MS-275- and to a lesser extent Trichostatin A- and SAHA-treated Raji cells significantly up regulated T lymphocytes proliferation which was reduced by about 50% by a 4-1BB blocking recombinant protein, while MS-275- but neither Trichostatin A- nor SAHA-treated cells up-regulated IFNgamma secretion by T lymphocytes. Our results identify 4-1BBL/4-1BB as a downstream target of HDACi, especially of MS-275 anti-leukemia action in vitro. Thus, HDACi such as MS-275 displaying dual TNF-dependent proapoptotic and costimulatory activities might be favored for inclusion in HDACi-based anti-cancer therapeutic strategies.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 327 330 327 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Hehlgans1">[1]</xref>
###xml 332 335 332 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Locksley1">[2]</xref>
###xml 555 558 551 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Moore1">[3]</xref>
###xml 560 563 556 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Knight1">[4]</xref>
###xml 629 632 625 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Zerafa1">[5]</xref>
###xml 769 772 765 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Watts1">[6]</xref>
###xml 878 879 874 875 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 888 895 884 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 984 987 980 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Melero1">[7]</xref>
###xml 989 992 985 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Shuford1">[8]</xref>
###xml 1318 1321 1314 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Insinga1">[9]</xref>
###xml 1323 1327 1319 1323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Nebbioso1">[10]</xref>
###xml 739 745 <span type="species:ncbi:10090">murine</span>
###xml 750 755 <span type="species:ncbi:9606">human</span>
Members of the Tumor Necrosis Factor ligands and receptors Superfamily (TNFSF) are both secreted and membrane-bound factors that regulate proliferation, activation, differentiation, maturation and survival or programmed cell death of lymphoid, myeloid and other haematopoietic, as well as various non-haematopoietic cell types [1], [2]. TNFSF are also implicated in various acquired or genetic diseases, and have been diversely involved in the control of carcinogenesis. While TNFalpha or TNFR1,2/TNFRSF1A,1B targeting induce tumor development resistance [3], [4], TRAIL/TNFSF10 deficiency accelerates hematological malignancies [5]. Furthermore, several TNFSF have demonstrated significant antitumor potential in a number of pre-clinical murine and human tumor models [6]. Notably, the finding that agonistic 4-1BB monoclonal antibodies can greatly enhance the expansion of CD8+ T cells in vivo and eradicate established tumors raised great interest in 4-1BB as a therapeutic target [7], [8]. Hence, strategies that aim to control TNFSF functions are intensively pursued, including the use of recombinant proteins, specific monoclonal antibodies, and by gene transfer. Recently, the tumor-selective action of histone deacetylase inhibitors (HDACi) was shown to involve TRAIL induction in acute myeloid leukemia cells [9], [10], paving the road to drug-based antitumor therapeutic strategies targeting TNFSF functions.
###end p 4
###begin p 5
###xml 104 108 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Drummond1">[11]</xref>
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Minucci1">[12]</xref>
###xml 258 266 258 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 271 278 271 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 552 556 552 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Drummond1">[11]</xref>
###xml 557 561 557 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Saito1">[13]</xref>
###xml 814 818 814 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Saito1">[13]</xref>
###xml 819 823 819 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Yoshida1">[16]</xref>
###xml 907 917 907 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF/CDKN1A</italic>
###xml 950 957 950 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF10</italic>
###xml 992 1000 992 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1063 1066 1063 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Insinga1">[9]</xref>
###xml 1068 1072 1068 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Nebbioso1">[10]</xref>
###xml 1074 1081 1074 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 1097 1104 1097 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF10</italic>
###xml 1144 1148 1144 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Nebbioso1">[10]</xref>
###xml 1261 1265 1261 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Kim1">[17]</xref>
###xml 1283 1287 1283 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Leoni1">[18]</xref>
###xml 1325 1329 1325 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Maeda1">[19]</xref>
###xml 1331 1335 1331 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Magner1">[20]</xref>
HDACi represent a new class of antitumor agents acting on histone deacetylase (HDAC) enzymatic activity [11], [12]. Despite the widespread role of HDAC in the transcriptional regulation of gene expression, HDACi are relatively non-toxic to normal cells both in vitro and in vivo, allowing to their use in anti-cancer therapeutic strategies. However, it remains unclear how HDACi exert this cancer cell-selective activity. HDACi are able to induce cell cycle arrest, differentiation, and both intrinsic and extrinsic apoptotic cell death of tumor cells [11]-[13]. Many HDACi have been identified, including the hydroxamate compounds Trichostatin A (TSA) and Suberoylanilide hydroxamic acid (SAHA) that are potent nanomolar HDACi, and the benzamide derivative MS-275, a non hydroxamate micromolar inhibitor of HDACs [13]-[16]. Previous reports have shown that these HDACi up-regulate transcription of the p21/WAF/CDKN1A cell-cycle inhibitor and induce TNFSF10 transcription, accounting for the in vitro HDACi-induced G1 arrest and extrinsic apoptosis, respectively [9], [10]. In vivo, knocking down TNFSF10 impairs the antitumor effect of MS-275 [10], but antitumor activity of HDACi may further involve additional biological effects such as reduced angiogenesis [17] and inflammation [18], as well as increased immunogenicity [19], [20].
###end p 5
###begin p 6
###xml 29 42 29 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9/4-1BBL</italic>
In this study, we identified TNFSF9/4-1BBL as a HDACi target that can mediate anti-leukemia allogeneic leukocyte response.
###end p 6
###begin title 7
Materials and Methods
###end title 7
###begin title 8
Cells, Culture condition
###end title 8
###begin p 9
###xml 131 154 131 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila melanogaster</italic>
###xml 271 272 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 119 123 <span type="species:ncbi:9913">calf</span>
###xml 131 154 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Jurkat T cells (JA16 clone), Raji cells and U937 cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum. Drosophila melanogaster SL2 cells were maintained in Insect-X-Press medium (BioWhittaker) supplemented with 10% FCS at 25degreesC without CO2.
###end p 9
###begin title 10
HDACIs and other reagents
###end title 10
###begin p 11
Three HDACi were used in this study: Trichostatin A (TSA) was obtained from Sigma, MS-275 and SAHA were obtained from Alexis. Cycloheximide (CHX) and Mithramycin A (MA) were obtained from SIGMA.
###end p 11
###begin title 12
Plasmid constructs
###end title 12
###begin p 13
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
The primers used for the pTNFSF9 constructs were:
###end p 13
###begin p 14
###xml 1 7 1 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 13 44 13 44 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CAGGGAGAGAGACACAGAGACAGAG-3&#8242;</named-content>
pTNFSF9 (1), 5'-CAGGGAGAGAGACACAGAGACAGAG-3';
###end p 14
###begin p 15
###xml 1 7 1 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 13 45 13 45 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GATCTCTTTCCACCCACTGCAGAGGC-3&#8242;</named-content>
pTNFSF9 (2), 5'-GATCTCTTTCCACCCACTGCAGAGGC-3';
###end p 15
###begin p 16
###xml 1 7 1 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 13 40 13 40 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GACGAGGGGAAAGGCTCTGGG-3&#8242;</named-content>
pTNFSF9 (3), 5'-GACGAGGGGAAAGGCTCTGGG-3';
###end p 16
###begin p 17
###xml 1 7 1 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 13 43 13 43 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGCCTCCTTTTGTAGCCAAGCAGC-3&#8242;</named-content>
pTNFSF9 (4), 5'-GGCCTCCTTTTGTAGCCAAGCAGC-3'
###end p 17
###begin p 18
###xml 19 51 19 51 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GACGAGAGACTGCGGGAAGACACAGC-3&#8242;</named-content>
and the 3' primer: 5'-GACGAGAGACTGCGGGAAGACACAGC-3'. The PCR products were cloned into the reporter vector pGL3-Basic adapted to the Gateway technology (a gift from T.Virolle). Whole nucleotide sequences from these constructs were confirmed by sequencing.
###end p 18
###begin title 19
Site-directed Mutagenesis
###end title 19
###begin p 20
###xml 1 7 1 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
pTNFSF9 (3) was used as a template for mutagenesis performed by the QuickChange site-directed mutagenesis method (Stratagene). The primers used to obtain Sp points mutants are:
###end p 20
###begin p 21
###xml 19 21 19 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</bold>
###xml 29 31 29 31 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</bold>
###xml 36 37 36 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</bold>
###xml 4 54 4 54 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGAAAGGCTCTG<bold>TT</bold>CTGGGAAG<bold>TT</bold>GCGTG<bold>T</bold>CCGCGGGCGGAGG-3&#8242;;</named-content>
m1, 5'-GGAAAGGCTCTGTTCTGGGAAGTTGCGTGTCCGCGGGCGGAGG-3';
###end p 21
###begin p 22
###xml 20 22 20 22 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</bold>
###xml 27 29 27 29 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</bold>
###xml 33 35 33 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</bold>
###xml 4 52 4 52 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGGCGTGGCCGCG<bold>TT</bold>CGGAG<bold>TT</bold>GCGT<bold>TT</bold>CCGCGGGCGGAGG-3&#8242;;</named-content>
m2, 5'-GGGCGTGGCCGCGTTCGGAGTTGCGTTTCCGCGGGCGGAGG-3';
###end p 22
###begin p 23
###xml 19 21 19 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</bold>
###xml 26 28 26 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</bold>
###xml 32 33 32 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</bold>
###xml 4 53 4 53 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGCGTGGCCGCG<bold>TT</bold>CGGAG<bold>TT</bold>GCGT<bold>T</bold>GCCTCCTTTTGTAGCC-3&#8242;.</named-content>
m3, 5'-GGCGTGGCCGCGTTCGGAGTTGCGTTGCCTCCTTTTGTAGCC-3'.
###end p 23
###begin p 24
Mutations were confirmed by DNA sequencing.
###end p 24
###begin title 25
RNA extraction and RT-PCR
###end title 25
###begin p 26
###xml 191 197 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 202 207 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 268 274 264 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 285 321 281 317 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTTTCACTTGCGCTGCACCTGCAGCCACTG-3&#8242;</named-content>
###xml 335 365 331 361 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TATCAACGTCCAACTTGGGGAAGG-3&#8242;</named-content>
###xml 375 380 371 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 391 415 387 411 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTCATCCCTGAGCTGAAC-3&#8242;</named-content>
###xml 429 453 425 449 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGGTCTTACTCCTTGGAG-3&#8242;</named-content>
###xml 554 559 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 580 586 558 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 656 662 628 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 676 681 648 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
Total RNA was isolated from the cells using the RNeasy mini kit (Qiagen) according to the manufacturer's protocol. 2 microg of total RNA was reversed transcribed into cDNA. The expression of TNFSF9 and GAPDH mRNA was analyzed by RT-PCR using the following primers for TNFSF9: forward, 5'-GTTTCACTTGCGCTGCACCTGCAGCCACTG-3' and reverse, 5'-TATCAACGTCCAACTTGGGGAAGG-3'; and for GAPDH, forward, 5'-GTCATCCCTGAGCTGAAC-3' and reverse, 5'-GGGTCTTACTCCTTGGAG-3'. Amplification was performed with denaturation at 94degreesC for 50 s, annealing at 60degreesC (for GAPDH) or 65degreesC (for TNFSF9) for 45 s and extension at 72degreesC for 45 s. The PCR products for TNFSF9 (466 bp) and GAPDH (613 bp) were separated by electrophoresis on a 3% agarose gel and visualized by staining with ethidium bromide.
###end p 26
###begin title 27
Quantitative RT-PCR
###end title 27
###begin p 28
###xml 321 328 321 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007085-t001">Table 1</xref>
###xml 785 786 763 764 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 950 951 928 929 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 965 970 943 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1074 1075 1048 1049 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1096 1097 1066 1067 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1101 1102 1071 1072 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1113 1114 1083 1084 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1167 1168 1129 1130 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1217 1218 1175 1176 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1255 1256 1209 1210 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1439 1443 1393 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Mitsiades1">[47]</xref>
Primer pairs for seventeen TNFSF ligands and twenty-four receptors were incorporated into a low-density array (Assay on Demand, Applied Biosystems). Three endogenous controls were added to the assay set. Three genes were added that represent genes previously described as being either up- or down-regulated by HDACi (see Table 1 for a complete list of genes included in this array). PCR was developed as recommended by the manufacturer. Briefly, 5 microl cDNA (equivalent to 100 ng of total RNA) was mixed with TaqMan Universal Mix (Applied Biosystems) and loaded into 1 sample port. Thermal cycler conditions were as follows: 2 minutes at 50degreesC, 15 s at 95degreesC, 60 s at 60degreesC for 40 cycles. Capture of fluorescence was recorded on the ABI Prism 7900HT scanner, and the CT was calculated for each assay using Sequence Detection System Software 2.1 (Applied Biosystems). Normalization of quantitative-PCR assays was conducted using the CT value of the GAPDH endogenous control. Samples were then converted to a fold change ratio described using standard Delta CT formula where DeltaCT = CT target - CT average endogenous controls. Thereafter, DeltaDeltaCT values were calculated by subtracting the DeltaCT value of each target from the DeltaCT of the calibrator (untreated samples). Clustering of quantitative-PCR data was conducted by Pearson correlation and visualized using the program TIGR Multiexperiment Viewer (MeV) () [47].
###end p 28
###begin title 29
List of genes included in the quantitative RT-PCR low-density array.
###end title 29
###begin p 30
###xml 146 152 146 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
Real time quantitative PCR was performed using a LightCycler rapid thermal cycler (Roche) according to the manufacturer's conditions. Primers for TNFSF9 and GAPDH used were from Applied Biosystems (TaqMan(R) Gene Expression Assays).
###end p 30
###begin title 31
Flow cytometry analysis
###end title 31
###begin p 32
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 135 140 <span type="species:ncbi:10090">mouse</span>
The cells were treated with HDACi for 4, 8, 24 and 48 h before flow cytometric analysis. Briefly, 2x105 cells were incubated with anti-mouse IgG-PE (Beckman Coulter) or anti-4-1BBL antibodies (BD Pharmingen) at 4degreesC for 30 minutes. After three washes with phosphate-buffered saline (PBS) supplemented with 2% FCS, the cells were subjected to flow cytometric analysis. Samples were analyzed on a FACScan (Becton Dickinson) and analyzed by CellQuest software.
###end p 32
###begin title 33
Nuclease digestion of purified nuclei and southern blotting
###end title 33
###begin p 34
###xml 81 85 81 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Castellano1">[21]</xref>
###xml 673 677 653 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Castellano1">[21]</xref>
###xml 757 787 737 767 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CTGCTGATCGATGGGCCCCTGAGC-3&#8242;</named-content>
###xml 792 823 772 803 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GACCTCGGTGAAGGGAGTCCGGCTG-3&#8242;</named-content>
Nuclei were purified and submitted to nuclease digestion as previously described [21]. Briefly, cells were lysed at 4degreesC in 0.2% NP40 buffer followed by nuclease digestion using DNase I (10 min at 4degreesC). Proteinase K-treated DNA was next purified by phenol extraction. Purified DNA (30 microg) was digested with Sac I and the fragments generated were separated by electrophoresis. Each size marker was generated by digesting genomic DNA (10 microg) with restriction enzymes as indicated in figure legends. After transfer to nylon membranes (Hybond-N+, Amersham Pharmacia Biotech), DNA was UV-cross-linked and membranes were prehybridized, as previously described [21]. The specific probes were synthesized by PCR using the following primer pairs: 5'-CTGCTGATCGATGGGCCCCTGAGC-3' and 5'-GACCTCGGTGAAGGGAGTCCGGCTG-3'. After random primer labeling, denatured DNA probes were allowed to hybridize for at least 16 h at 68degreesC followed by extensive washes and autoradiography.
###end p 34
###begin title 35
Electroporation and Luciferase Assays
###end title 35
###begin p 36
###xml 2 3 2 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 121 127 117 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
107 Jurkat T cells were electroporated using Bio-Rad gene pulser II (250 V, 25 ms) with 10 microg of pGL3 or the various TNFSF9 promoter-driven firefly luciferase constructs together with 5 microg of beta-globine Renilla luciferase plasmid (pRL-beta). The cells were incubated for 1 h before they were collected, washed in PBS and lysed to determine the luciferase activity by using the dual luciferase reporter assay according to manufacturer's instructions (Promega), and read using a luminometer (Dynex). The transfection efficiency was normalized to Renilla luciferase activity and corrected for protein content as determined by the Bradford protein assay (Bio-Rad). The reported values represent the average of three independent transfections, with standard deviation as errors bars.
###end p 36
###begin p 37
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 440 445 <span type="species:ncbi:9606">Human</span>
SL2 cells (2x105) were plated in 24-well plates and transfection was carried out using Effectene Transfection Reagent (Qiagen). Each well was transfected with 200 ng of reporter plasmid and with pHMW-Sp1 (0 to 600 ng) supplemented, when necessary, with empty vector (pHMW) to equalize the total DNA transfected to 1 microg. Fourty-eight hours after transfection, cells were harvested and assayed for luciferase activity as described above. Human pHMW-Sp1 and its control vector (pHMW) were gifts from Dr Murphy, T.D, Carnegie Institution of Washington, USA.
###end p 37
###begin title 38
Allogeneic mixed leukocyte reaction
###end title 38
###begin p 39
###xml 121 122 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 177 178 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 626 627 604 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 721 722 695 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 391 396 <span type="species:ncbi:9606">human</span>
Raji cells were treated for 24 hours with TSA (250 nM), MS-275 (2.5 microM) or SAHA (2.5 microM). After irradiation, 1x105 stimulator B lymphomas cells (Raji) were added to 2x105 PBMCs in each well of 96-well U-bottomed culture plates. OKT3 (0.5 microg/ml) was immobilized onto the surface of the plates (ON, 4degreesC). Cells were cultured in presence or absence of 1 microg/ml recombinant human 4-1BB-Fc and DR3-Fc (R&D systems) or control Nectine 4-Fc (a gift from M.Lopez). Recombinant proteins were added to the cultures at the same time as cells. Lymphocyte proliferation after 5 days of culture was measured by adding [3H]-thymidine (0,2 microCi/well) to the wells for the last 18 h and the cells were harvested. [3H] incorporation was determined using a TopCount scintillation counter (Packard Instrument).
###end p 39
###begin title 40
Cytokine assay
###end title 40
###begin p 41
IFN-gamma levels were measured by ELISA using a cytokine detection kit (BD Biosciences) according to the manufacturer's instructions.
###end p 41
###begin title 42
Electrophoretic mobility shift assays
###end title 42
###begin p 43
###xml 75 79 75 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Osborn1">[22]</xref>
###xml 206 210 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Bradford1">[23]</xref>
###xml 325 332 325 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007085-t002">Table 2</xref>
###xml 419 423 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-VanLint1">[24]</xref>
###xml 1442 1448 <span type="species:ncbi:9986">rabbit</span>
Nuclear extracts were prepared by a rapid method described by Osborn et al [22]. All buffers contained complete protease inhibitors (Roche). Protein concentrations were determined by the method of Bradford [23]. The DNA sequences of the coding strand of the double-stranded oligonucleotides used for this study are listed in Table 2. Electrophoretic mobility shift assays (EMSAs) were performed as described previously [24]. Briefly, nuclear extract (10 microg of protein) was first incubated on ice for 10 min in the absence of probe and specific competitor DNA in a 16 microl reaction mixture containing 10 microg of DNase-free BSA (Amersham Biosciences), 1-2 microg of poly(dI-dC) (Amersham Biosciences) as non-specific competitor DNA, 50 microM ZnCl2, 0.25 mM DTT, 20 mM HEPES (pH 7.3), 60 mM KCl, 1 mM MgCl2, 0.1 mM EDTA and 10% (v/v) glycerol. 20 000 c.p.m. of probe (10-40 fmol) was then added to the mixture with or without a molar excess of an unlabeled specific DNA competitor, and the mixture was incubated for 20 min on ice. Samples were subjected to electrophoresis at room temperature on 6% polyacrylamide gels at 120 V for 2-3 h in 1x TGE buffer (25 mM Tris-acetate, pH 8.3), 190 mM glycine and 1 mM EDTA). Gels were dried and autoradiographed for 24-48 h at -70degreesC. For supershift assays, polyclonal antibodies against Sp1 (sc-059X), Sp2 (sc-643X), Sp3 (sc-644X), Sp4 (sc-645X), (Santa Cruz Biotechnology), or a purified rabbit immunoglobulin (IgG) were added to the reaction mixture and incubated for 30 min on ice before the addition of the radiolabeled probe.
###end p 43
###begin title 44
Primers used for Electrophoretic Mobility Shift Assays.
###end title 44
###begin p 45
(Only forward primers are indicated).
###end p 45
###begin title 46
Results
###end title 46
###begin title 47
Up-regulation of TNFSF9 mRNA in HDACi-stimulated leukemia cell lines
###end title 47
###begin p 48
###xml 325 332 321 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g001">Fig. 1A</xref>
Modification of histone and alpha tubulin acetylation by HDAC inhibition was first investigated in the Jurkat T cell leukemia cell lines using different treatment times and dosages of the hydroxamic-derived Trichostatin A (TSA), the Suberoylanilide hydroxamic acid (SAHA), and the benzamide-derived MS-275 HDACi. As shown in Fig. 1A, while the three HDACi induced dose-dependent acetylation of histone H4, which peaked at 16 hours of treatment, only SAHA and TSA induced alpha tubulin acetylation, as expected from the known incapacity of MS-275 to impact on the specific acetylation of alpha tubulin by HDAC 6.
###end p 48
###begin title 49
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
Analysis of TNFSF9 gene expression profiles induced by HDACi in leukaemia cell lines.
###end title 49
###begin p 50
###xml 895 899 867 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HPRT</italic>
###xml 901 910 873 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;Actin</italic>
###xml 912 926 881 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21/WAF/CDKN1A</italic>
###xml 931 937 900 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 985 990 954 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1238 1244 1207 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1249 1254 1218 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1460 1466 1421 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1471 1476 1432 1437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1551 1557 1512 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1662 1668 1623 1629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
(A) Jurkat JA16 cells were incubated with SAHA (lanes 2-5; 0.5, 1, 2.5 and 5 microM), MS-275 (lanes 6-9; 0.5, 1, 2.5 and 5 microM) or TSA (lanes 10-13, 50, 100, 200, 500 nM), or mock-treated (lane 1) for 16 hours, followed by cell lysis, SDS-PAGE and immunoblotting using the indicated antibodies (left panel). In parallel, Jurkat JA16 cells were incubated with SAHA (2 microM), TSA (200 nM), MS-275 (2 microM) or mock-treated (DMSO) for 6, 16 or 24 hours, as indicated, followed by cell lysis, SDS-PAGE and immunoblotting using the indicated antibodies (right panel). (B) Jurkat JA16 cells were incubated with TSA (500 nM), MS-275 (2,5 microM) or SAHA (2,5 microM) for 8 hours and left unstimulated or stimulated by PMA (20 ng/ml) and Ionomycin (1 microg/ml) for 4 hours. Following incubation time, total mRNA was extracted and analyzed by Transcription Low Density Array. Results obtained for HPRT, betaActin, p21/WAF/CDKN1A and TNFSF9 are presented as expression ratios relative to GAPDH transcript levels. The scale shows the level of expression, where red indicates increased gene expresssion, and the intensity of color correlated to the magnitude change. Black indicates no change. (C) mRNA from (B) were analyzed by RT-PCR, using TNFSF9 and GAPDH primer pairs. (D) Jurkat JA16, RAJI and U937 cells were mock-treated or incubated with TSA (250 nM), MS-275 (1 microM) and SAHA (1 microM) for 4, 8 or 24 hours. Total mRNA was extracted and transcripts of TNFSF9 and GAPDH were analyzed by RT-PCR. These conditions were compromized to compare for TNFSF9 transcript detection and modulation by HDAC inhibition in different cell types producing distinct basal TNFSF9 transcript levels.
###end p 50
###begin p 51
###xml 188 195 188 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007085-t001">Table 1</xref>
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF</italic>
###xml 529 539 529 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF/CDKN1A</italic>
###xml 623 630 623 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g001">Fig. 1B</xref>
###xml 695 700 695 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF</italic>
###xml 780 784 780 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Minucci1">[12]</xref>
###xml 786 790 786 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Johnstone1">[25]</xref>
###xml 808 814 808 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 828 833 828 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF</italic>
###xml 848 853 848 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF</italic>
###xml 944 951 944 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g001">Fig. 1B</xref>
###xml 1010 1016 1010 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1048 1052 1048 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HPRT</italic>
###xml 1057 1067 1057 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946; Actin</italic>
###xml 1098 1103 1095 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1210 1216 1207 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1270 1277 1267 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g001">Fig. 1C</xref>
###xml 1393 1399 1390 1396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1581 1586 1578 1583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1623 1630 1620 1627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g001">Fig. 1D</xref>
These experimental conditions were developped to investigate for the transcriptional modulation of genes of the TNFSF familly using a transcription low-density array (see list of genes in Table 1). Modification of TNFSF mRNA profiles induced by 8 h treatment with TSA, SAHA, and MS-275 were determined in Jurkat cells, followed or not by a 4 h stimulation by a combination of phorbol ester (PMA) and calcium ionophore (Ionomycin) to up-regulate gene transcription. As compared to untreated cells, each HDACi strongly induced p21/WAF/CDKN1A cell cycle inhibitor, used here as control for HDACi-regulated gene transcription (Fig. 1B). Significant (above 2-fold and up to 15-fold) modifications of TNFSF transcript levels were also noted, consistent with previous reports (not shown [12], [25]). Interestingly, TNFSF9 was the only TNFSF out of the 17 TNFSF present in the array to be modulated by the three HDACi (not shown). Indeed, as showed in Fig. 1B, the three investigated HDACi up-regulated mRNA levels of TNFSF9 by two- to eight-fold, but not HPRT and beta Actin mRNA levels, as normalized to GAPDH levels. Transcriptional induction by the combination of PMA and Ionomycin further increased HDACi-induced TNFSF9 mRNA levels, which was confirmed by RT-PCR analysis (Fig. 1C), as well as by quantitative real time RT-PCR (data not shown). Time course RT-PCR experiments further showed that TNFSF9 mRNA levels were up-regulated by the three HDACi in Jurkat and also in the Raji Burkit B lymphoma and U937 myeloid cell lines, in a time-dependent manner, as compared to endogenous GAPDH levels, yet with distinct kinetics (Fig. 1D).
###end p 51
###begin title 52
Up-regulation of TNFSF9 by HDACi does not require de novo protein synthesis and is not associated with DNAse I hypersensitive chromatin remodeling
###end title 52
###begin p 53
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 242 249 242 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g002">Fig. 2A</xref>
###xml 251 257 251 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 399 406 399 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g002">Fig. 2B</xref>
###xml 425 431 425 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 564 578 564 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g002">Fig. 2A and 2B</xref>
###xml 626 632 626 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 898 902 898 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Levine1">[26]</xref>
###xml 1171 1192 1171 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9 mRNA levels by</italic>
###xml 1254 1260 1254 1260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1465 1472 1465 1472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g002">Fig. 2C</xref>
###xml 1582 1588 1582 1588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1951 1957 1951 1957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
To explore the mechanism of HDACi-induced TNFSF9 up-regulation, Jurkat cells were pre-incubated with the protein synthesis inhibitor, cycloheximide (CHX) followed by further incubation for 8 h in the presence or absence of HDACi. As shown in Fig. 2A, TNFSF9 mRNA levels were not reduced by CHX treatment, but instead were observed to be markedly up-regulated. This was further confirmed by QRT-PCR (Fig. 2B), suggesting that TNFSF9 mRNA levels are regulated by neosynthesized cellular factors. However, this effect appeared to not be modulated by HDAC inhibition (Fig. 2A and 2B), indicating that the observed upregulation of TNFSF9 mRNA levels by HDACi does not appear to require neosynthesized cellular factors, and suggests the direct implication of transcriptional regulatory mechanisms. In eukaryotes, chromatin is recognized as an important modulator of transcriptional regulatory mechanisms [26]. Increased histone acetylation, such as following HDAC activity pharmacological inhibition, neutralizes the positive charge of lysine residues, allowing a more "open" chromatin structure that facilitates transcription. We thus investigated whether the upregulation of TNFSF9 mRNA levels by HDACiinvolved chromatin remodeling. DNAse I digestion of the TNFSF9 locus followed by indirect end-labeling identified two major dose-dependent DNase I hypersensitive sites (DHSI and II) that were mapped to the 5' regulatory promoter region and between exon 1 and exon 2 (Fig. 2C), respectively. This pattern remained unchanged following HDACi treatment, indicating that the modulation of TNFSF9 mRNA levels by HDACi expression does not involve detectable DNAse I hypersensitive chromatin remodeling within the region under study, however, this study does not exclude localized promoter architecture modifications. The hypersensitivity of the promoter region to DNAse I digestion in unstimulated cells correlated with the basal constitutive transcription of TNFSF9 in Jurkat T cells (data not shown).
###end p 53
###begin title 54
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 65 72 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
Modulation of TNFSF9 transcript levels by HDACi does not require de novo protein synthesis and does not require TNFSF9 promoter region chromatin remodeling.
###end title 54
###begin p 55
###xml 228 234 216 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 239 244 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 322 328 310 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g001">Fig. 1</xref>
###xml 442 449 430 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 529 532 517 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sac</italic>
###xml 544 552 532 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 628 634 616 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 909 915 897 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1064 1067 1052 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sac</italic>
###xml 1081 1084 1069 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nsi</italic>
###xml 1097 1100 1085 1088 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nhe</italic>
###xml 1113 1117 1101 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hinc</italic>
###xml 1131 1134 1119 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xho</italic>
###xml 1150 1153 1138 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bgl</italic>
Jurkat JA16 cells were left unstimulated (UN) or were incubated for 1 hour with CHX (10 microg/ml) and then treated for 8 hours by TSA (250 nM), MS-275 (1 microM) and SAHA (1 microM). Total mRNA was extracted and transcripts of TNFSF9 and GAPDH were analysed by PCR (A) and quantified by real-time PCR (B) as described in Fig. 1. (C) Nuclei from Jurkat T cells left unstimulated (UN), or treated with TSA (500 nM) for 18 hours, were digested in vivo with increasing amounts of DNase I (0, 30, 40, 50, 60 and 70 U/ml) followed by SacI digestion in vitro and indirect end-labeling (lower panel). The schematic organization of the TNFSF9 locus, showing the indirect end-labeling and southern blotting strategy, as well as the DNaseI hypersensitive sites (DHS) identified in the course of the present study are depicted in the upper panel. The position of the probe used for the southern blotting, as well as the TNFSF9 exon 1-3 are showed. Hypersensitive regions DHSI and DHSII are shown on the left. Molecular weight markers (MM) are a double digest of naked DNA by SacI (12641 bp), NsiI (9180 bp), NheI (6850 bp), HincII (5006 bp), XhoI (2390 bp) and BglII (1918 bp).
###end p 55
###begin title 56
Identification and mapping of HDACi responsive elements within the TNFSF9 promoter region
###end title 56
###begin p 57
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 149 156 149 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g003">Fig. 3A</xref>
###xml 279 286 279 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g003">Fig. 3B</xref>
###xml 341 347 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 458 465 458 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g003">Fig. 3C</xref>
###xml 469 475 469 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 481 487 481 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 496 502 496 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 725 732 725 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g003">Fig. 3C</xref>
###xml 840 846 840 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1021 1027 1021 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g003">Fig. 3</xref>
###xml 70 75 <span type="species:ncbi:9606">human</span>
To determine whether HDACi activate TNFSF9 transcription, we isolated human genomic fragments containing the predicted TNFSF9 5' regulatory regions (Fig. 3A). These genomic DNA fragments were inserted upstream to the luciferase reporter gene in the pGL3 basic plasmid construct (Fig. 3B). Promoter activity of the corresponding constructs (pTNFSF9 (1)-(4)) was assayed by measuring firefly luciferase activity after transient transfection in Jurkat T cells (Fig. 3C). pTNFSF9(1), pTNFSF9(2) and pTNFSF9(3) transcriptional activity was induced up to 12 fold by TSA treatment, indicating the presence of TSA-inducible element(s) within the 985, 398 and 140 bp genomic DNA fragment controlling firefly luciferase transcription (Fig. 3C). In contrast, firefly luciferase activity was not induced by TSA treatment of cells transfected with the pTNFSF9(4) or pGL3 basic empty constructs, indicating that these TSA-inducible element(s) are contained between nucleotide -140 and -65 according to the translation initiation site (Fig. 3). Similar results were observed using different HDACi in different cell lines (data not shown).
###end p 57
###begin title 58
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 47 52 <span type="species:ncbi:9606">human</span>
Identification of TSA response elements in the human TNFSF9 promoter.
###end title 58
###begin p 59
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 75 83 75 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">boldface</italic>
###xml 293 299 293 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 717 720 712 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RLU</italic>
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 287 292 <span type="species:ncbi:9606">human</span>
(A) DNA sequence of a 400-bp human TNFSF9 promoter region. The ATG site is boldface (to which we assigned the position nucleotide + 1). Putative Sp1/Sp3 binding sites are boxed. Putative CCAAT boxes are underlined. (B) The constructs were generated by cloning progressively 5'-truncated human TNFSF9 promoter fragments into the pGL3/basic luciferase vector. Negative numbers denote bp distances from translational start codon. (C) Jurkat cells were transiently cotransfected with the indicated reporter constructs and pRL-beta to control for transfection efficiency. Transfected cells were either left untreated or treated with TSA (500 nM) for 16 hours. Data are the average +/- SD of three independent experiments. RLU, relative light units.
###end p 59
###begin title 60
Identification of HDACi responsive elements within the TNFSF9 promoter region
###end title 60
###begin p 61
###xml 200 204 200 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Jin1">[27]</xref>
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Zhang1">[32]</xref>
###xml 236 243 236 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pTNFSF9</italic>
###xml 564 571 564 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g003">Fig. 3A</xref>
###xml 743 750 743 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g004">Fig. 4A</xref>
###xml 845 851 845 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1017 1023 1017 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1201 1207 1201 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1216 1222 1216 1222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1282 1289 1282 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g004">Fig. 4B</xref>
###xml 1384 1390 1384 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1691 1695 1691 1695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Castellano1">[21]</xref>
###xml 1697 1701 1697 1701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Kavurma1">[33]</xref>
###xml 1716 1723 1716 1723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g004">Fig. 4C</xref>
###xml 2071 2078 2071 2078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g004">Fig. 4B</xref>
Previous studies have shown that conserved cis-regulatory elements, particularly Sp1 and CCAAT boxes, located in the promoters of several genes are responsible for transcriptional activation by HDACi [27]-[32]. Sequence analysis of the pTNFSF9 region contained between the nucleotides -140 and -65 upstream to the translation initiation site using MatInspector (Genomatix Software, Munich, Germany) and TESS (Transcription Element Search System, CBIL, US) allowed the identification of consensus binding sites for transcriptions factors of the Sp (GC-box) family (Fig. 3A). Mutations of the individual GC-box, as well as combined mutations were performed to evaluate the functional significance of these putative Sp binding sites. As shown in Fig. 4A, individual mutations did not significantly alter basal promoter activity, yet TSA-activated pTNFSF9(3) promoter luciferase activity was reduced by about 25-70% in Jurkat T cells, depending on the individual mutated GC-rich sequence, whereas the combined mutation (pTNFSF9(3) m4) abolished both the basal- and the TSA-induced activity, as compared to the control pGL3 basic reporter construct. Similar results were obtained upon transfection of the pTNFSF9(3) and pTNFSF9(3) m4 promoter constructs in the U937 and Raji cell lines (Fig. 4B). These results identify the GC-boxes studied as important mediators of HDACi inducibility of TNFSF9 promoter activity. To gain more insights into the specificity of GC-rich sequences in TSA-induced transcription, a previously described p-486TNFSF6/FasL promoter construct containing functional GC-rich sequences was transfected into Jurkat cells and analyzed for its responsiveness to TSA treatment ([21], [33]). As shown in Fig. 4C, despite transcriptional induction of this promoter construct by PMA plus Ionomycin treatment, TSA did not stimulate p-486TNFSF6/FasL-mediated transcription. On the opposite, TSA co-treatment down-regulated PMA plus Ionomycin-induced transcription, indicating that the presence of functional GC-rich sequences does not predict TSA-responsiveness (Fig. 4B).
###end p 61
###begin title 62
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
TSA-induced TNFSF9 promoter activity depends on GC-boxes sequences.
###end title 62
###begin p 63
###xml 88 109 88 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 116 123 116 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hatched</italic>
###xml 207 213 207 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">filled</italic>
###xml 1437 1443 1414 1420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
(A) The different pTNFSF9 (3)-luc mutated constructs were generated as described under "Materials and Methods". The hatched boxes represent putative GC-boxes. The mutations in theses sites are symbolized by filled boxes. Jurkat cells were transiently cotransfected with the indicated reporter construct and the pRL-beta to control for transfection efficiency. Cells were left unstimulated or treated with TSA (500 nM) for 16 hours. Means +/- SD of three independent experiments are shown. Basal transcriptional activities were 7.7+/-1.8, 13.5+/-4.9, 96.7+/-19.2, 222.2+/-20.3, 133.5+/-7.6 and 175+/-81.7 RLU for the pGL3, pTNFSF9 (3) m4, pTNFSF9 (3) m3, pTNFSF9 (3) m2, pTNFSF9 (3) m1 and pTNFSF9 (3), respectively. (B) The indicated pTNFSF9 (3)-luc constructs were transfected in U937 (left panel) and Raji (right panel) cell lines and analyzed as described in (A). (C) The p-486TNFSF6/FasL promoter construct was transfected in Jurkat cells and analyzed as described in (A) except that PMA (20 ng/ml) and Ionomycin (1 microg/ml) were added, as indicated. Means +/- SD of three independent experiments are shown. (D) RT-PCR was performed on total mRNA isolated from Jurkat cells pretreated with the GC-box binding inhibitor mithramycin A (MA) for 1 hour followed by incubation in the presence TSA (250 nM) for 8 hours. (E) Increasing concentrations of MA (100, 200 and 500 nM) was added to the cells 1 hour after transfection with the pTNFSF9 (3) reporter plasmid, followed by the addition of TSA (500 nM) 1 hour later. The cells were harvested 16 hours after the addition of TSA and processed for luciferase assay. Means +/- SD of three independent experiments are shown.
###end p 63
###begin title 64
Effect of the mithramycin A DNA intercalating agent on HDACi-induced TNFSF9 gene expression
###end title 64
###begin p 65
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Bhuiyan1">[34]</xref>
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Miller1">[35]</xref>
###xml 163 169 163 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 228 235 228 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g004">Fig. 4C</xref>
###xml 273 279 273 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 393 399 393 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 465 472 465 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g004">Fig. 4D</xref>
###xml 594 600 594 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
Mithramycin A is an anti-tumor antibiotic which inhibits transcription from promoters containing GC-rich DNA sequences [34], [35]. We thus evaluated HDACi-induced TNFSF9 expression following mithramycin A treatment. As shown in Fig. 4C, mithramycin A prevented TSA-induced TNFSF9 mRNA up-regulation. Consistent with the decreased levels of TNFSF9 mRNA, mithramycin A also reduced TSA-induced pTNFSF9(3)-mediated transcriptional activity in a dose-dependent manner (Fig. 4D). Collectively, this data strongly indicates that GC-box interacting transcription factors are involved in HDACi-induced TNFSF9 expression.
###end p 65
###begin title 66
Sp1/Sp3 transcription factors bind to TNFSF9 promoter GC box elements in vitro and increase its promoter activity
###end title 66
###begin p 67
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 171 178 171 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g005">Fig. 5A</xref>
###xml 380 387 380 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g005">Fig. 5B</xref>
###xml 773 780 773 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g005">Fig. 5C</xref>
###xml 958 965 958 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g005">Fig. 5C</xref>
###xml 1340 1347 1340 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g005">Fig. 5D</xref>
###xml 1604 1611 1604 1611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g005">Fig. 5D</xref>
###xml 1707 1714 1707 1714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g005">Fig. 5D</xref>
###xml 1843 1850 1843 1850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g005">Fig. 5D</xref>
###xml 2197 2204 2197 2204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g005">Fig. 5D</xref>
###xml 2360 2367 2360 2367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g005">Fig. 5D</xref>
###xml 2530 2536 2530 2536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 2716 2720 2716 2720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Liu1">[36]</xref>
###xml 2722 2726 2722 2726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Suske1">[37]</xref>
###xml 2767 2773 2767 2773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 2948 2954 2948 2954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 3005 3014 3005 3014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g005">Figure 5E</xref>
###xml 2589 2594 <span type="species:ncbi:9606">human</span>
###xml 2856 2861 <span type="species:ncbi:9606">human</span>
In order to assess the binding of members of the Sp family to the GC-boxes that we identified in the TNFSF9 promoter region, we designed double-stranded oligonucleotides (Fig. 5A). These oligonucleotides were radiolabeled and tested in electrophoretic mobility shift assays (EMSA) for DNA-protein interactions with nuclear extracts from mock-treated and TSA-treated Jurkat cells (Fig. 5B). Retarded protein-DNA complexes were observed using the three distinct GC-box oligonucleotides and TSA treatment did not induce detectable modification of the observed pattern of retarded protein-DNA complexes. To evaluate the sequence specificity of the binding to these GC-boxes, we performed competition EMSAs using different unlabeled double-stranded competitor oligonucleotides (Fig. 5C). The specificity of the protein binding was demonstrated because their formation was inhibited by competition with molar excesses of the unlabeled homologous oligonucleotides (Fig. 5C, lane 3). In contrast, these complexes were not competed by mutated version of the oligonucleotides (lane 4). Similar results were observed for the three GC-boxes. To identify directly the Sp family members within the retarded complexes, we performed supershift assays using specific antibodies directed against individual members of the Sp family of transcription factors (Fig. 5D). The wild-type probe was incubated with nuclear extracts from Jurkat cells and polyclonal antibodies directed against Sp1 and/or Sp3 were added to the binding reaction mixture. The Sp1 antibody selectively supershifted the major slower migrating complex (Fig. 5D, lane 3) and the Sp3 antibody resulted in the strong decrease of the faster migrating complex (Fig. 5D, lane 4). We confirmed these results when both the anti-Sp1 and anti-Sp3 antibodies were included in the same binding reaction (Fig. 5D, lane 5). In contrast, the binding pattern was not affected by the addition of the antibodies directed against other Sp proteins (Sp2 and Sp4) (data not shown), showing that the two complexes did not seem to involve these other proteins. Moreover, the binding pattern was not affected by the addition of purified IgG, used as a negative control (Fig. 5D, lane 6). Again, similar results were obtained using the three GC-boxes. Of note, TSA treatment did not appear to detectably alter Sp1 and/or Sp3 binding (Fig. 5D). Overall, these results demonstrate that Sp1 and Sp3 transcription factors interact with the GC-box (renamed Sp site hereafter in the manuscript) located in the TNFSF9 promoter region. SL2 cells are devoid of endogenous human Sp family transcription factors and thus represent a useful model to investigate Sp-dependent transcriptional mechanisms [36], [37]. SL2 cells were cotransfected with the pTNFSF9(3) promoter construct along with pHMW-Sp1 (insect expression vectors encoding for human Sp1). Over expression of Sp1 in SL2 cells resulted in an increased expression of the pTNFSF9(3) promoter construct in a dose-dependent manner (Figure 5E). Similar results were obtained upon expression of Sp3 transcription factor (not shown).
###end p 67
###begin title 68
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
Sp proteins bind to the GC-box located in the TNFSF9 promoter.
###end title 68
###begin p 69
###xml 1304 1310 1296 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1599 1602 1591 1594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RLU</italic>
###xml 1018 1024 <span type="species:ncbi:9986">rabbit</span>
(A) Nucleotide sequence of the three wild-type GC-box oligonucleotides probes are shown with underlined bases corresponding to the mutated bases. (B) The three wild-type GC-box oligonucleotides probes were incubated with nuclear extracts from Jurkat cells (10 microg) and treated or not for 4 hours with TSA (250 nM) in the absence or in the presence of unspecific competitor (dI-dC). The figure shows only the specific retarded bands of interest. (C) The three wild-type GC-box oligonucleotide probes were incubated with nuclear extracts from Jurkat cells (10 microg) in the absence (lane 2) or in the presence of the unlabeled oligonucleotide (lane 3) or of the mutated unlabeled oligonucleotide (lane 4). The figure shows only the specific retarded bands of interest. (D) Nuclear extracts from Jurkat cells treated or not for 4 hours with TSA (250 nM) were incubated in the absence of antibody or in the presence of antibodies directed against Sp1 and/or Sp3 (as indicated at the top of each lane) or with purified rabbit IgG as negative control, before addition of the oligonucleotide probe. The figure shows only the specific retarded bands of interest. Arrows indicate specific retarded DNA-protein complexes corresponding to Sp1 and Sp3. (E) SL2 cells were transiently cotransfected with pGL3 or pTNFSF9 (3)-luc and with various amounts of the Sp1 expression construct (pHMW-Sp1) or the empty vector (pHMW) and processed for luciferase assays. Values were normalized relative to the protein concentration of the cellular lyzates. The experiment was repeated three times with similar results. RLU, relative light units.
###end p 69
###begin title 70
HDACi-induced TNFSF9 expression increases anti-leukemia allogeneic leukocyte response
###end title 70
###begin p 71
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 290 297 290 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g006">Fig. 6A</xref>
###xml 593 594 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 797 804 785 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g006">Fig. 6B</xref>
###xml 1003 1007 987 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Gramaglia1">[38]</xref>
###xml 1008 1012 992 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Takahashi1">[40]</xref>
###xml 1237 1243 1215 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 1334 1341 1310 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g006">Fig. 6B</xref>
###xml 1451 1458 1423 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g006">Fig. 6B</xref>
###xml 1661 1668 1633 1640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g006">Fig. 6C</xref>
###xml 1903 1910 1875 1882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g006">Fig. 6C</xref>
###xml 2199 2203 2167 2171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Migone1">[41]</xref>
###xml 2530 2537 2498 2505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007085-g006">Fig. 6E</xref>
In an attempt to determine the functional significance of HDACi-induced TNFSF9 mRNA levels, 4-1BBL protein expresssion levels and function were evaluated. Time course Flow Cytometry experiments evidenced the up-regulation of 4-1BBL cell surface expression by the three HDACi in Raji cells (Fig. 6A). Ralji cells were next incubated in the presence of HDACi for 24 hours followed by gamma-irradiation to prevent further cell proliferation and co-culture with purified T lymphocytes from healthy donors. IFNgamma secretion was determined by ELISA and T lymphocyte proliferation was assessed by [3H]-thymidine uptake. MS-275-stimulated Raji cells significantly up-regulated IFNgamma secretion by 7 fold (t student, p<0,01), which was prevented by the recombinant 4-1BB-Fc but not control-Fc protein (Fig. 6B), indicating a requirement for 4-1BB/4-1BBL interaction for IFNgamma secretion stimulated by HDACi-treated Raji cells. TcR/CD3 triggering to activate T lymphocytes to up-regulate cell surface 4-1BB [38]-[40], induced a marked up-regulation of IFNgamma secretion which was further significantly increased by co-culture of stimulated T cells with MS-275-stimulated Raji cells as compared to untreated Raji cells (6675,8+/-409,3 pg/ml versus 4607,4+/-167,4 pg/ml; t student: p<0,01), in a 4-1BB/4-1BBL interaction dependent-manner (Fig. 6B). In contrast to MS-275, TSA- and SAHA-stimulated Raji cells did not stimulate increased IFNgamma secretion (Fig. 6B). However, HDACi-stimulated Raji cells significantly up-regulated T cell proliferation, as compared to untreated Raji cells, using either TSA and SAHA (t student, p<0,05) or MS-275 (t student, p<0,01) (Fig. 6C). Addition of the recombinant 4-1BB-Fc but not control-Fc protein efficiently prevented up-regulation of T lymphocyte proliferation by HDACi-stimulated Raji cells, implicating 4-1BB/4-1BBL interactions in the increased proliferation (Fig. 6C). To further examine for the specificity of 4-1BB/4-1BBL interactions in this HDACi-stimulated mixed lymphoid reaction, DR3-Fc recombinant protein was used as an additional control. Indeed, TL1A/TNFSF15-DR3 interactions have been implicated in T cell proliferation and IFNgamma secretion [41]. Using the DR3-Fc recombinant protein to block these interactions, only 4-1BB-Fc, but neither the control-Fc nor the DR3-Fc recombinant proteins efficiently prevented up-regulation of T lymphocyte proliferation by HDACi-stimulated Raji cells, specifically implicating 4-1BB/4-1BBL interactions in the increased proliferation (Fig. 6E)
###end p 71
###begin title 72
Induced proliferation of normal allogeneic leukocytes by Raji cells treated with HDACi.
###end title 72
###begin p 73
###xml 241 242 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 308 309 308 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 640 641 620 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 509 514 <span type="species:ncbi:9606">human</span>
(A) FACS analysis of 4-1BBL expression on HDACi-treated Raji cells for 4, 8, 24 and 48 hours as indicated. Results are presented as % of positive cells. The data shown are from one experiment representative of a total of two. (B) PBMCs (2x105) of healthy donor were incubated for 5 days with Raji cells (1x105) treated or not for 24 hours with TSA (250 nM), MS-275 (2.5 microM) or SAHA (2.5 microM). PBMCs were stimulated or not with immobilized OKT3 (0,5 microg/ml) in the presence or absence of recombinant human 4-1BB-Fc (1 microg/ml) or control-Fc protein (1 microg/ml), as indicated, and proliferation was measured by incorporation of 3H-thymidine during the last 18 hours of culture. Supernatants from unstimulated (C) and from OKT3-stimulated (D) cell cultures were collected at 48 hours of culture and assayed for IFNgamma by ELISA. Values are means of triplicates +/- SD and this experiment is representative of two independent experiments. * p<0,05 and ** p<0,01 (t student). (E) As in (B), except that DR3-Fc recombinant protein was added (1 microM/ml), as indicated. Values are means of triplicates +/- SD.
###end p 73
###begin title 74
Discussion
###end title 74
###begin p 75
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
In this study, we identified 4-1BBL/TNFSF9 as a transcriptionaly activated target of three distinct HDACi in leukemia cell lines and most importantly that MS-275-induced 4-1BB/4-1BBL interactions potentiated anti-leukemia allogeneic leukocyte response, hence providing novel molecular insights into the antileukemia mechanisms of action of HDACi.
###end p 75
###begin p 76
###xml 74 78 74 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Glick1">[42]</xref>
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Ruefli1">[44]</xref>
###xml 195 199 195 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Glaser1">[45]</xref>
###xml 200 204 200 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-VanLint2">[48]</xref>
###xml 293 297 293 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Peart1">[43]</xref>
###xml 451 465 451 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A/p21/WAF</italic>
###xml 465 469 465 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Huang1">[49]</xref>
###xml 471 478 471 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF10</italic>
###xml 478 482 478 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Nebbioso1">[10]</xref>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Vigushin1">[50]</xref>
###xml 543 549 543 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 737 743 737 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 942 948 942 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1079 1085 1079 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1205 1211 1205 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1275 1281 1275 1281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1448 1452 1448 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Saito1">[13]</xref>
###xml 1454 1458 1454 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Ammanamanchi1">[51]</xref>
###xml 1460 1464 1460 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Camarero1">[52]</xref>
###xml 1509 1513 1509 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Won1">[53]</xref>
###xml 1606 1612 1606 1612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1690 1696 1690 1696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1737 1744 1737 1744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1774 1780 1774 1780 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 1914 1920 1914 1920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
Regulation of gene expression is important for HDACi antitumor activities [42]-[44]. Expression profiling studies have identified that limited sets of target genes (2-10%) are regulated by HDACi [45]-[48], yet more recent studies have suggested that this number might have been underestimated [43]. Nonetheless, the molecular basis to explain how HDACi impact gene expression remains poorly understood at the genome level. As previously described for CDKN1A/p21/WAF[49], TNFSF10[10] and other HDACi-activated genes [50], we show here that the TNFSF9 promoter region contains functional Sp1/Sp3 transcription factors binding sites that are critical for its HDACi-induced gene transcription. But how Sp1/Sp3 transcription factors modulate TNFSF9 transcription in an HDACi-regulated manner remains to be established. Using the indirect-end labeling technique, DNAse I hypersensitive sites (DHSI and II) were identified, DHSI being mapped to the TNFSF9 minimal promoter region containing the Sp1/Sp3 DNA binding sites. DHSI was detected in unstimulated Jurkat cells displaying basal TNFSF9 transcription and was not detectably altered upon HDACi treatment, in agreement with the transcriptional activation of TNFSF9 promoter constructs by HDACi and suggesting that HDACi-induced TNFSF9 transcription did not involve DNase I-sensitive large chromatin remodeling events. The transcriptional activity of Sp1 family members can be modulated by acetylation [13], [51], [52] and both Sp1 and Sp3 can interact with HDAC [53], suggesting a role for Sp1 and/or Sp3 acetylation in the Sp1/Sp3-dependent, HDACi-regulated TNFSF9 induction. Alternatively, Sp1/Sp3 may recruit acetylated co-factors allowing TNFSF9 transcriptional induction. To asses the in vivo binding of Sp factors to the TNFSF9 promoter region, we attempted to perform chromatin immunoprecipitation assays. Preliminary experiments showed low enrichement of the TNFSF9 promoter region in Sp1 immunoprecipitates, as compared to control antibodies, that were also not detectably modified by TSA treatment in agreement with previous observations ((Nebbioso, 2005 #173] and data not shown).
###end p 76
###begin p 77
###xml 103 109 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 153 159 153 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 260 266 260 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">per se</italic>
###xml 331 337 331 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 637 643 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 734 740 734 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
Of interest, nonetheless, mithramycin A abrogated both HDACi-stimulated endogenous and promoter-driven TNFSF9 transcription, yet it did not affect basal TNFSF9 transcription, supporting the hypothesis that acetylation of Sp1/Sp3 or associated factors, and not per se Sp1/Sp3 chromatin-recruitment, was required for HDACi-regulated TNFSF9 induction. Consistent with this hypothesis, EMSA experiments did not reveal increased Sp1/Sp3 DNA binding upon HDACi treatment. Collectively, these results support a model where protein acetylation induced by HDACi increases the transcriptional activity of Sp1/Sp3-dependent complexes seated on the TNFSF9 promoter. The mechanisms of acetylation of Sp1/Sp3 or associated factors in HDACi-induced TNFSF9 transcription remains to established.
###end p 77
###begin p 78
###xml 440 447 436 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 546 553 542 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 604 607 600 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Watts1">[6]</xref>
###xml 609 612 605 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Melero1">[7]</xref>
###xml 789 792 785 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Shuford1">[8]</xref>
###xml 794 798 790 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Takahashi1">[40]</xref>
###xml 1465 1469 1461 1465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Wilcox1">[54]</xref>
###xml 1596 1600 1592 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Wilcox2">[55]</xref>
###xml 1602 1606 1598 1602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Wilcox3">[56]</xref>
###xml 1695 1702 1691 1698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1754 1758 1746 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Wilcox4">[57]</xref>
###xml 1954 1958 1942 1946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Kaplan1">[58]</xref>
###xml 1963 1964 1951 1952 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1972 1973 1960 1961 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2174 2178 2158 2162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Boehm1">[59]</xref>
###xml 2230 2234 2214 2218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Fallarino1">[60]</xref>
###xml 2312 2316 2296 2300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Qin1">[61]</xref>
###xml 2371 2375 2355 2359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Nakajima1">[62]</xref>
One important finding of the present study was the functional up-regulation of 4-1BBL by MS-275, as evidenced by enhanced T cell proliferation and IFNgamma production in mixed peripheral blood leukocytes co-culture experiments. While TRAIL up-regulation was convincingly shown to contribute to the selective HDACi-induced apoptosis of tumor cells, our results provide first evidence that up-regulated 4-1BBL might further contribute to the in vivo anticancer action of HDACi such as MS-275. There has been ample evidence demonstrating the robust in vivo anti-tumor immune responses upon 4-1BB triggering [6], [7]. This effect is largely interpreted by 4-1BB signaling on tumor-specific T cells that can enhance proliferation and CTL activity, and can prevent activation-induced cell death [8], [40]. Consistently, co-cultures of HDACi-treated Raji cells with T cell receptor-stimulated peripheral blood leukocytes enhanced T cell proliferation as compared to untreated Raji cells. This proliferative response was blocked in the presence of competing 4-1BB-Fc, but not by DR3-Fc recombinant protein, showing that 4-1BB/4-1BBL interaction was specifically required for this HDACi-enhanced T cell proliferative response. More recent studies have further revealed additional mechanisms that may account for 4-1BB anti-tumor effects. Firstly, 4-1BB signaling is able to prevent and rescue T cells from immune tolerance, promoting regression of poorly immunogenic tumors [54]. Secondly, 4-1BB expression on non-T cell populations, including natural killer cells and dendritic cells has been implicated [55], [56]. Finally, 4-1BB stimulation modifies the distribution pattern of tumor-specific T cells in vivo, in a manner that is largely dependent on IFNgamma [57]. IFNgamma, a pleiotropic cytokine secreted by activated T cells and NK cells, plays a central role in both the innate and adaptive immune response to a variety of pathogens and transformed cells [58]. CD4+ and CD8+ T cells have been shown to mediate tumor rejection in an IFNgamma-dependent fashion through different mechanisms, including up-regulation of molecules critical for antigen processing and presentation [59], differentiation of fully competent effector cells [60], secretion of angiostatic chemokines by stromal cells present within a tumor [61], and regulation of T-cell migration to the tumor site [62]. In this study, co-cultures of MS-275-treated Raji cells with T cell receptor-stimulated peripheral blood leukocytes enhanced T lymphocyte IFNgamma secretion, as compared to untreated Raji cells. Increased IFNgamma secretion was blocked in the presence of competing 4-1BB/TNFRSF9-Fc recombinant protein, showing that 4-1BB/4-1BBL interactions were required. Importantly, induction of IFNgamma was also observed in the absence of T cell activation, and was completely blocked in the presence of the 4-1BB-Fc recombinant protein, indicating that induction of IFNgamma by MS-275-treated Raji cells occurred through 4-1BB triggering and could occur in the absence of T cell activation.
###end p 78
###begin p 79
###xml 593 597 589 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Maeda1">[19]</xref>
###xml 942 950 938 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 958 962 954 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vivo</italic>
###xml 992 996 988 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Saito1">[13]</xref>
###xml 998 1002 994 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Butler1">[63]</xref>
###xml 1004 1008 1000 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Jaboin1">[64]</xref>
###xml 1650 1651 1646 1647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1706 1710 1702 1706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007085-Uno1">[65]</xref>
###xml 1885 1890 <span type="species:ncbi:9606">human</span>
Despite similar levels of induction of 4-1BBL transcription and cell surface expression by TSA, SAHA and MS-275, only MS-275 potentiated IFNgamma secretion in mixed leukocyte reactions and also provided more efficient T lymphocyte proliferative responses in these assays. These results suggest that compared to TSA and SAHA, MS-275 can provide additional specific signalling to improve further immune responses. Previous reports have shown that HDACi can induce the expression of CD86/B7.2 costimulatory molecule in acute myeloid leukemia (AML) cells and freshly isolated AML clinical samples [19]. Taken together with our present finding that HDACi can enhance expression of yet another costimulatory molecule, 4-1BBL, this data further supports HDACi, especially MS-275, as antitumor drugs to be used in immunotherapeutic clinical approaches. HDACi have been shown to induce growth arrest, differentiation, and/or apoptosis of cancer cells in vitro and in vivo tumor-bearing animals models [13], [63], [64]. In association with the proapoptotic effect of HDACi, the enhancement of costimulatory molecules on leukemia blasts could augment tumor immunogenicity, increasing specific CTL activity against tumor cells. Combinatorial treatment modulating both apoptotic and costimulatory molecules may be more effective for reinforcing host immunity and eradicating tumors. This point is supported by a recent study by Uno et al. who showed that induction of tumor cell apoptosis by an agonistic antibody to TRAILR2/DR5, combined with T cell activation by CD40 and 4-1BB agonistic monoclonal antibodies, potently and rapidly stimulated tumor-specific CD8+ T cells capable of eradicating pre-established tumors [65]. It is noteworthy that HDACi treatment did not induce 4-1BBL transcription in breast-derived tumor cells lines, nor did it induce significant 4-1BBL transcription in primary human peripheral blood lymphocytes, suggesting leukemia specific modulation of 4-1BBL by HDACi treatment (BV, data not shown).
###end p 79
###begin p 80
###xml 380 386 380 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFSF9</italic>
###xml 449 456 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
In conclusion, we have demonstrated that HDACi can modulate the expression of 4-1BBL costimulatory molecule in B leukemia cell line model, which can enhance T cell responses towards the tumor cells. Further studies are now required to examine these effects using primary cells from patients with chronic lymphocytic leukemia (CLL) and to determine in animal models whether 4-1BBL/TNFSF9 up-regulation contributes to HDACi-induced anti-tumor effects in vivo. The distinct capacity of MS-275 as compared to other HDACi to modulate these T cell responses will also require further investigation.
###end p 80
###begin title 81
References
###end title 81
###begin article-title 82
The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.
###end article-title 82
###begin article-title 83
The TNF and TNF receptor superfamilies: integrating mammalian biology.
###end article-title 83
###begin article-title 84
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis.
###end article-title 84
###begin article-title 85
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice.
###end article-title 85
###begin article-title 86
Cutting edge: TRAIL deficiency accelerates hematological malignancies.
###end article-title 86
###begin article-title 87
TNF/TNFR family members in costimulation of T cell responses.
###end article-title 87
###begin article-title 88
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.
###end article-title 88
###begin article-title 89
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.
###end article-title 89
###begin article-title 90
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway.
###end article-title 90
###begin article-title 91
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells.
###end article-title 91
###begin article-title 92
Clinical development of histone deacetylase inhibitors as anticancer agents.
###end article-title 92
###begin article-title 93
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.
###end article-title 93
###begin article-title 94
###xml 104 109 <span type="species:ncbi:9606">human</span>
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
###end article-title 94
###begin article-title 95
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.
###end article-title 95
###begin article-title 96
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
###end article-title 96
###begin article-title 97
Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.
###end article-title 97
###begin article-title 98
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes.
###end article-title 98
###begin article-title 99
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
###end article-title 99
###begin article-title 100
Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells.
###end article-title 100
###begin article-title 101
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors.
###end article-title 101
###begin article-title 102
###xml 28 33 <span type="species:ncbi:9606">human</span>
Active transcription of the human FASL/CD95L/TNFSF6 promoter region in T lymphocytes involves chromatin remodeling: role of DNA methylation and protein acetylation suggest distinct mechanisms of transcriptional repression.
###end article-title 102
###begin article-title 103
###xml 60 88 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B.
###end article-title 103
###begin article-title 104
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
###end article-title 104
###begin article-title 105
###xml 106 141 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
A transcriptional regulatory element is associated with a nuclease-hypersensitive site in the pol gene of human immunodeficiency virus type 1.
###end article-title 105
###begin article-title 106
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
###end article-title 106
###begin article-title 107
Transcription regulation and animal diversity.
###end article-title 107
###begin article-title 108
Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y.
###end article-title 108
###begin article-title 109
Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites.
###end article-title 109
###begin article-title 110
###xml 153 158 <span type="species:ncbi:9606">human</span>
Transcriptional regulation of the transforming growth factor b type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells.
###end article-title 110
###begin article-title 111
Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites.
###end article-title 111
###begin article-title 112
Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
###end article-title 112
###begin article-title 113
Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3.
###end article-title 113
###begin article-title 114
Ets-1 positively regulates Fas ligand transcription via cooperative interactions with Sp1.
###end article-title 114
###begin article-title 115
Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases.
###end article-title 115
###begin article-title 116
Mithramycin selectively inhibits transcription of G-C containing DNA.
###end article-title 116
###begin article-title 117
Regulation of histone deacetylase 4 expression by the SP family of transcription factors.
###end article-title 117
###begin article-title 118
Transient transfection of Schneider cells in the study of transcription factors.
###end article-title 118
###begin article-title 119
Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand.
###end article-title 119
###begin article-title 120
cDNA sequences of two inducible T-cell genes.
###end article-title 120
###begin article-title 121
Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal.
###end article-title 121
###begin article-title 122
TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.
###end article-title 122
###begin article-title 123
###xml 96 101 <span type="species:ncbi:9606">human</span>
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.
###end article-title 123
###begin article-title 124
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.
###end article-title 124
###begin article-title 125
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.
###end article-title 125
###begin article-title 126
Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.
###end article-title 126
###begin article-title 127
Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer.
###end article-title 127
###begin article-title 128
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
###end article-title 128
###begin article-title 129
The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.
###end article-title 129
###begin article-title 130
Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
###end article-title 130
###begin article-title 131
Targeted histone deacetylase inhibition for cancer therapy.
###end article-title 131
###begin article-title 132
Acetylated sp3 is a transcriptional activator.
###end article-title 132
###begin article-title 133
Histone deacetylase inhibitors stimulate mitochondrial HMG-CoA synthase gene expression via a promoter proximal Sp1 site.
###end article-title 133
###begin article-title 134
###xml 68 73 <span type="species:ncbi:9606">human</span>
###xml 134 139 <span type="species:ncbi:9606">human</span>
Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells.
###end article-title 134
###begin article-title 135
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
###end article-title 135
###begin article-title 136
Cutting edge: Expression of functional CD137 receptor by dendritic cells.
###end article-title 136
###begin article-title 137
Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity.
###end article-title 137
###begin article-title 138
Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy.
###end article-title 138
###begin article-title 139
###xml 92 96 <span type="species:ncbi:10090">mice</span>
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.
###end article-title 139
###begin article-title 140
Cellular responses to interferon-gamma.
###end article-title 140
###begin article-title 141
Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1.
###end article-title 141
###begin article-title 142
CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.
###end article-title 142
###begin article-title 143
###xml 178 182 <span type="species:ncbi:10090">mice</span>
A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice.
###end article-title 143
###begin article-title 144
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
###end article-title 144
###begin article-title 145
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
###end article-title 145
###begin article-title 146
###xml 37 41 <span type="species:ncbi:10090">mice</span>
Eradication of established tumors in mice by a combination antibody-based therapy.
###end article-title 146
###begin p 147
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 147
###begin p 148
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Work in YC lab was supported by grants from the Institut National de la Sante et de la Recherche Medicale (INSERM) and by grants from the Association Nationale de Recherche contre le SIDA (ANRS), the Institut National de Recherche contre le Cancer (INCa), the Association de Recherche contre le Cancer (ARC). Work in C.V.L. lab was supported by grants from the Belgian Fund for Scientific Research (FRS-FNRS, Belgium), the Televie-Program of the FRS-FNRS, the Action de Recherche Concertee du Ministere de la Communaute Francaise (Universite Libre de Bruxelles, ARC program ndegrees 04/09-309), the Programme d'Excellence "Cibles" of the Region Wallonne and the Internationale Brachet Stiftung. C.V.L. is Directeur de Recherches of the FRS-FNRS, and BV was fellow from ARC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 148

